- Proof-of-activity now established for PBGENE-HBV, the first and only clinical modality designed to eliminate covalently closed circular DNA (cccDNA) and inactivate integrated DNA, with the goal of ...
SAN JOSE, Calif., Sept. 8, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...
The first cohort of a new program that aims to help fill gaps in rural health care was unveiled Monday at the University of Alberta's Edmonton campus. The Northern Alberta Medical Program is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback